peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical announces sudden death of CEO Göran Arvidson

8 Nov 2017, 08:00
Regulatory information

"It is with great regret that we announce the passing of Göran Arvidson which is both deeply tragic and completely unexpected," said Ulf Wiinberg, Chairman of Hansa Medical. "Göran Arvidson has left us suddenly and unexpectedly. Our thoughts go to Göran's family and to those closest to him."

Göran Arvidson was recruited to Hansa Medical as CFO in January 2015. He became acting CEO shortly afterwards and was appointed permanent CEO on April 30th the same year. He has had long and successful career in the pharmaceutical industry, including senior positions at Pharmacia and Biovitrum (Sobi).

"With his solid experience from the pharmaceutical industry and through his strong and genuine commitment, Göran has been an outstanding strong and skilled leader for Hansa Medical, which, in our view, has become a very promising pharmaceutical company. We are very grateful for the time that we had Göran at the helm," said Ulf Wiinberg.

Chairman Ulf Wiinberg will serve as acting CEO and board member Birgit Stattin Norinder will take over the role as chairman of the board until further notice.

This information is information that Hansa Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 8:00 PM CET on November 8, 2017.  

Emanuel Björne, Vice President Business Development and Investor Relations
Mobile: +46 70 717 5477

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and acute autoimmune indications. The company also has a strong pipeline of preclinical assets that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing translating the Hansa Medical technology into relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.